Quarterly Outlook
Equity outlook: The high cost of global fragmentation for US portfolios
Charu Chanana
Chief Investment Strategist
The implications of “Liberation Day” reciprocal tariffs & the subsequent uncertainty that came along with them, carried into this week in full force. A global selloff in equity markets & broad risk-off sentiment saw investors looking for safe havens in currencies and gold as the looming recession fears started to amplify & the VIX briefly exceeded 60. Equity Index moves included some of the largest seen in years, with Nasdaq closing a day up +12% & a heavy selloff in US treasuries saw 10yr yields surge 50bps in a significant move – which may have contributed to the US pulling the brakes on some tariffs in a 90-day pause announcement. Read more in this week’s key stories below: Tariff pause brings relief rally Treasury dump Investors seek shelter in currencies Big Pharma face targeted tariffs Next week we expect that tariff announcements and geopolitical developments will once again dominate. Scheduled earnings releases include Goldman Sachs (Mon), Johnson & Johnson, Bank of America, Citigroup (Tues), ASML, Abbott Laboratories (Weds), Taiwan Semiconductor, UnitedHealth, Netflix, American Express (Thurs). Focus will be as much on guidance and commentary around tariffs as much as the Q1 results. Key economic data to watch for are German Apr ZEW (Tues), China Q1 GDP, US Mar Retail Sales, Fed Chair Powell speaks (Weds), ECB interest rate decision, Atlanta Fed Q1 GDPNow (Thurs).
US President Trump announced a 90-day pause on higher reciprocal tariffs that were due to hit dozens of trade partners on Wednesday. In a sign of relief US equities posted historic gains with the S&P 500 surging 9.5% and the Nasdaq climbing 12.16%, its best single-day performance since 2001. The overall tariff angst remains unresolved with the bounce looking fragile.
Trump's tariff pause sparks rally
Bonds were the talk of the town this week, as 10-year treasuries spiked 50 basis points in a significant move to 4.5%. While the broader equity market selloff carried into the start of the week, US treasuries suddenly came under heavy selling pressure, which could have been a component of the decision from President Trump to hit pause on the dramatic reciprocal tariff program.
Why are bonds losing appeal in these uncertain times?
The US Dollar retreated for the fourth consecutive session this week as markets sought safe havens in the Euro, Japanese Yen, Swiss Franc, and Gold. The tariff escalations have led investors to demand higher yields for US debt, as the outlook for the US economy becomes bleaker and the tariff plans remain unclear. The Euro rallied to a three-year high, breaking the 100-month moving average, as German Bunds attracted investors. Meanwhile, the Japanese Yen has strengthened for four consecutive months.
SaxoTraderGO
Speaking at a fundraiser dinner for his Republican Party on Tuesday, Trump said: "We're going to be announcing very shortly a major tariff on pharmaceuticals.” a move that could end decades of low-cost global trade in medicines. In 2024, pharmaceuticals were the EU's largest export to the US, worth a reported $127bn (£100bn).
Potential tariffs for Pharma
Disclaimer
The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.
Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-gb/legal/disclaimer/saxo-disclaimer)